Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 3, 2024
Context: The filing serves as a Regulation FD disclosure to inform investors that senior management will reaffirm full-year 2024 financial guidance during upcoming industry conferences and meetings scheduled between September 3, 2024, and September 30, 2024.
Key Financial Metrics and Guidance
The filing provides specific forward-looking guidance for the fiscal year ending December 31, 2024 (FY 2024). No historical revenue, profit, cash flow, or debt figures are included in this specific document.
| Metric | FY 2024 Guidance |
|---|---|
| Diluted EPS (GAAP) | Approximately $12.81 |
| Adjusted EPS (Non-GAAP) | Approximately $16.00 |
Reconciliation of GAAP to Adjusted EPS:
- Amortization of identifiable intangibles: $0.50
- Put/call valuation adjustments (non-consolidating minority interest): $1.65
- Impact of exit of employer group commercial medical products business: $1.21
- Value creation initiatives: $0.80
- Cumulative net tax impact of non-GAAP adjustments: $(0.97)
Material Changes Versus Prior Period
The filing states that the current guidance is consistent with the guidance issued in Humana's press release dated July 31, 2024. No material changes to the previously issued guidance are reported in this document.
Outlook, Risks, and Management Commentary
Management Commentary: Management utilizes Adjusted EPS as a consistent indicator of core business operations for planning, decision-making, and incentive compensation. They assert that this non-GAAP measure, when presented alongside GAAP EPS, provides a comprehensive perspective on operating performance.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. These statements are subject to risks, uncertainties, and assumptions, including those detailed in the "Risk Factors" section of the Company's other SEC filings. The guidance is not a guarantee of future performance.
Key Facts for Investor Verification
- Verify the specific dates and times of the upcoming investor presentations on the Company's Investor Relations calendar.
- Confirm the reconciliation details between GAAP and Non-GAAP EPS in the Company's official earnings releases or 10-Q/10-K filings to understand the specific adjustments.
- Review the "Risk Factors" section in the most recent 10-K or 10-Q to understand the specific uncertainties affecting the $12.81 GAAP and $16.00 Adjusted EPS targets.
- Note that this 8-K does not contain actual historical financial results for the period ended September 3, 2024, only forward-looking guidance.